IMA
ImageneBio, Inc.
NASDAQ: IMA · HEALTHCARE · BIOTECHNOLOGY
$5.91
+0.00% today
Updated 2026-06-03
Market cap
$63.73M
P/E ratio
—
P/S ratio
83.32x
EPS (TTM)
$-4.78
Dividend yield
—
52W range
$4 – $18
Volume
0.4M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
3.3
Growth
D7.5
Quality
B+3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
1.9
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$24.00
+306.09%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy0 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.07x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-14.80M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $15.62M | $9.16M | $3.50M | $800000.00 | $0.00 |
| Net income | $-68.77M | $-68.17M | $-36.57M | $-45.35M | $-10.62M |
| EPS | — | — | — | — | $-4.78 |
| Free cash flow | $-75.54M | $-80.16M | $-46.00M | $-47.84M | $-14.80M |
| Profit margin | -440.29% | -744.17% | -1,044.80% | -5,668.63% | — |
Peer comparison
Smart narrative
ImageneBio, Inc. trades at $5.91. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.89, it sits in the grey zone.
Frequently asked questions
What is ImageneBio, Inc.'s stock price?
ImageneBio, Inc. (IMA) trades at $5.91, on a P/S of 83.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is ImageneBio, Inc. overvalued?
ImageneBio, Inc. carries a Smart Value Score of 30/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of ImageneBio, Inc. (IMA)?
The 12-month analyst consensus target is $24.00, about 306.1% above the current $5.91. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
ImageneBio, Inc.'s Altman Z-Score is 1.89, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio83.32x
ROE-36.55%
Beta—
50D MA$5.55
200D MA$7.21
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—